Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19173 | 0.88 | — | — | |
| SCHEMBL31674379 | 0.86 | PDE10A (0.45) | SMPD3APOBEC3AAPOBEC3GPDE10ADYRK1A | |
| SCHEMBL31338725 | 0.86 | PDE10A (0.45) | SMPD3APOBEC3AAPOBEC3GPDE10ADYRK1A | |
| Hydrochloric Acid SCHEMBL6894527 | 0.86 | PDE10A (0.45) | SMPD3APOBEC3AAPOBEC3GPDE10ADYRK1A | |
| Pyridine SCHEMBL28190620 | 0.82 | DYRK1A (0.41) | SMPD3APOBEC3AAPOBEC3GPDE10ADYRK1A | |
| SCHEMBL1369628 | 0.82 | PDE10A (0.42) | SMPD3APOBEC3AAPOBEC3GPDE10ADYRK1A | |
| M-Xylene SCHEMBL26641909 | 0.74 | ACHE (0.43) | APOBEC3AAPOBEC3GPDE10ADYRK1AALDH1A1 | |
| SCHEMBL15313356 | 0.73 | ABCG2 (0.48) | APOBEC3GPDE10AKDM4EALDH1A1MAPK1 | |
| SCHEMBL5051822 | 0.71 | IRAK4 (0.38) | SMPD3APOBEC3AAPOBEC3GKDM4EHPGD | |
| Formamide SCHEMBL19667843 | 0.70 | SMPD3 (0.33) | SMPD3APOBEC3AAPOBEC3GAXLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R & D Investments, S.A. (PT) | 2024-03-19 | — | — | US | disclosed |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2022-06-02 | — | — | US | disclosed |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-12-07 | — | — | US | disclosed |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-08-17 | — | — | US | disclosed |
| US-10934298-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | BIAL—BioTech Investments, Inc. (PT) | 2021-03-02 | — | — | US | disclosed |
| US-20200385390-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2020-12-10 | — | — | US | disclosed |
| US-10570135-B2 | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190330213-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-10-31 | — | — | US | disclosed |
| US-9840510-B1 | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-07 | — | — | US | disclosed |
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | SMPD3 530/4885APOBEC3A 320/4885APOBEC3G 228/4885 |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | GBA1, PARK7, GAA | SMPD3 243/4885APOBEC3A 863/4885APOBEC3G 707/4885 |
| US-20170349598-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | SMPD3 367/4885APOBEC3A 880/4885APOBEC3G 699/4885 |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | SMPD3 367/4885APOBEC3A 880/4885APOBEC3G 699/4885 |
| US-10934298-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | GBA1, GAA, PARK7 | SMPD3 244/4885APOBEC3A 763/4885APOBEC3G 720/4885 |
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | SMPD3 530/4885APOBEC3A 320/4885APOBEC3G 228/4885 |
| US-20190330213-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | SMPD3 367/4885APOBEC3A 880/4885APOBEC3G 699/4885 |
| US-10570135-B2 | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | SMPD3 530/4885APOBEC3A 320/4885APOBEC3G 228/4885 |
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | SMPD3 530/4885APOBEC3A 320/4885APOBEC3G 228/4885 |
| US-20200385390-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | SMPD3 530/4885APOBEC3A 320/4885APOBEC3G 228/4885 |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | SMPD3 530/4885APOBEC3A 320/4885APOBEC3G 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.